Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
复制标题
类风湿关节炎中的治疗性 B 细胞耗竭和再生：新兴模式和范式。
DOI：
10.1002/art.22020
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Silverman,GreggJ
中科院分区：
文献类型：
--
作者：
Silverman,GreggJ
在最近的对照临床试验(1-3项)中，使用抗CD20嵌合单抗利妥昔单抗的B细胞靶向治疗被证明对类风湿关节炎(RA)患者有效。然而，尽管这些抗CD20抗体输注已经变得越来越常见，特别是在血液学/肿瘤学实践中，这种FDA批准的治疗方式对大多数风湿病医生来说仍然是陌生的。虽然这些治疗可以预测地导致大多数可检测到的循环B淋巴细胞的丧失，但B细胞耗竭治疗对宿主免疫防御的更大影响现在才慢慢被揭示出来。在本期《关节炎和风湿病》中，Roll等人的报告(4)为我们理解这些治疗的免疫生物学后遗症提供了进一步的贡献，因为领先的研究小组已经开始描述由抗CD20治疗引起的B细胞室的中枢免疫生物学变化。
In recent controlled clinical trials (1–3), B cell–targeted therapy using rituximab, a chimeric anti-CD20 monoclonal antibody, was shown to be effective in patients with rheumatoid arthritis (RA). However, even though use of these anti-CD20 antibody infusions has become increasingly commonplace, especially in hematology/oncology practices, this FDA-approved therapeutic modality is still unfamiliar to most rheumatologists. Although these treatments predictably induce the loss of most detectable circulating B lymphocytes, the greater implications of B cell depletion therapy for host immune defenses are only now slowly being revealed. In this issue of Arthritis & Rheumatism, the report by Roll et al (4) provides further contributions to our understanding of the immunobiologic sequelae of these treatments, as leading research groups have begun to characterize the central immunobiologic changes in the B cell compartment that are induced by anti-CD20 treatment.